TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11000660
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral antacid, alugel hydroxide 300 mg)
Study: 7198209
Drug: Lecithin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithin (10 gm three times daily for 3 months)
Study: 7198209
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 gm three times daily for 3 months)
Study: 31626213
Drug: Medical non-elastic
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical non-elastic hypoallergenic patch (placebo)
Study: 24943808
Drug: Maternal use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal use of any antibiotics during pregnancy
Study: 24943808
Drug: Child's use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child's use of antibiotics during the first year of life
Study: 24943808
Drug: Child's use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child's use of amoxicillin
Study: 21344494
Drug: Additive tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additive tolterodine extended release (ER) 4 mg q.d.
Study: 17583187
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (CC) 8 mg once daily, with dosage adjustment to 16 mg if BP was not normalized
Study: 11243303
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (CC)
Study: 15612963
Drug: Long-acting beta-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta-agonist (LABA) treatment
Study: 15612963
Drug: Increased doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased doses of inhaled corticosteroid (ICS)
Study: 15612963
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of treatment
Study: 12377957
Drug: Distant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distant treatment failures
Study: 8592764
Drug: NANP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NANP vaccine
Study: 2767067
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (0.300 g.kg‐1 body mass)
Study: 2767067
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride placebo (0.045 g.kg‐1 body mass)
Study: 603002
Drug: Alphaxalone/alphadalone (0.036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphaxalone/alphadalone (0.036 ml/kg)
Study: 29027653
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 µg kg⁻¹
Study: 29027653
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 µg kg⁻¹
Study: 20214329
Drug: Puerarin preconditioning
Normalized name: Pueraria montana var. chinensis root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin preconditioning (0.6 g in 250 mL 5% glucose solution for intravenous dripping every day for one week before operation)
Study: 29301558
Drug: Perindopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (ACE inhibitor)
Study: 15062889
Drug: telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan (40 to 80 mg once daily)
Study: 15062889
Drug: valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (80 to 160 mg once daily)
Study: 3130687
Drug: Oxamniquine treatment
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxamniquine treatment
Study: 8005825
Drug: Etanidazole (ETA)
Normalized name: Tinidazole
DrugBank: Etanidazole (DB12736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etanidazole (ETA) with accelerated fractionation XRT 20 Gy BID to 40 Gy in 2 weeks and continuous infusion during brachytherapy
Study: 2551469
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg by metered dose inhaler twice a day)
Study: 31303567
Drug: Sertraline (n=1202)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (n=1202)
Study: 31303567
Drug: Fluoxetine (active-control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (active-control group; n=754)
Study: 30527258
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g Resistant Maltodextrin (RMD)
Study: 30527258
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g Resistant Maltodextrin (RMD)
Study: 30527258
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g Resistant Maltodextrin (RMD)
Study: 22849533
Drug: Aripiprazole (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (average final dose 7.8 mg/day, range 2.5-15 mg/day)
Study: 20026576
Drug: Therapy focused
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy focused on familiarizing patients with communicative functions of gestures and improving spatial precision of gestures
Study: 11225511
Drug: Therapy
Normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapy
Study: 20026576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ten patients tested repeatedly without interpolated therapy)
Study: 15876309
Drug: Levocetirizine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine treatment
Study: 10098759
Drug: Chemotherapy (alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (alternating courses of etoposide‐carboplatin and etoposide‐ifosfamide for a total of four courses) + 40 Gy local irradiation
Study: 10098759
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (combination of chemotherapy and local radiotherapy)
Study: 7596370
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy (prednisone with either cyclosporine or azathioprine) for 24 weeks
Study: 9111
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg bromazepam p.o.
Study: 31033512
Drug: Therapeutic anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic anticoagulation with heparin (target activated partial thromboplastin time between 50 and 70 s)
Study: 31033512
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose heparin (up to 12,000 U/24 hr aiming for activated partial thromboplastin time < 45 s)
Study: 3734264
Drug: Therapeutic anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic anticoagulation with heparin
Study: 31033512
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose heparin
Study: 29045553
Drug: S-1 (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle)
Study: 29045553
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2 in Japan, 75 mg/m2 at all other study sites; day 1 in a 3-week cycle)
Study: 23589097
Drug: Tailored home‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored home‐based exercise (HE; 1‐hour training), twice a week for 1 year
Study: 23589097
Drug: Group‐based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group‐based exercise (GE; 4‐hour sessions with approximately 1‐hour training), twice a week for 1 year
Study: 21159803
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of intravenous contrast at a rate of 2.5 ml s(‐1)
Study: 21159803
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of intravenous contrast at a rate of 2 ml s(‐1)
Study: 12949996
Drug: Gepirone immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone immediate-release (gepirone-IR)
Study: 12949996
Drug: Gepirone extended-release
Normalized name: gepirone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone extended-release (gepirone-ER, types 1, 2, and 3)
Study: 12949996
Drug: Gepirone extended-release
Normalized name: gepirone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone extended-release (gepirone-ER)
Study: 8150761
Drug: Cefepime 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2.0 g bd i.v.
Study: 8150761
Drug: Ceftazidime 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2.0 g tid i.v.
Study: 25176615
Drug: Entecavir 0.5mg
Normalized name: ENTECAVIR 0.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5mg daily
Study: 18431235
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid therapy (15 mg/day of methyltertrahydrofolate for 1 year)
Study: 18431235
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid therapy in high-risk subgroup (older recipients and those with coronary artery disease)
Study: 18431235
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid therapy in lower-risk subgroup
Study: 12718214
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (20 mg/day for 20 days)
Study: 12718214
Drug: Inhaled benacort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled benacort (400 micrograms twice a day for 20 days)
Study: 8471327
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant combination chemotherapy (AMF); 5‐fluorouracil 500 mg/m2, doxorubicin 40 mg/m2, mitomycin C 6 mg/m2 (n = 30) once every 3 weeks for six cycles
Study: 8471327
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjuvant chemotherapy) (n = 31)
Study: 8471327
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant combination chemotherapy (AMF)
Study: 3898908
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (80 micrograms in the epidural test dose of bupivacaine)
Study: 3898908
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (infusion designed to produce comparable plasma concentrations)
Study: 24132613
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg daily
Study: 28594249
Drug: School nurse-administered
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: School nurse-administered inhaled corticosteroids (ICS)
Study: 28594249
Drug: Control (home-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (home-administered ICS)
Study: 25891550
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a (IM IFNβ‐1a) 30 μg
Study: 22857881
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support with whey peptide and low-intensity exercise therapy
Study: 20300048
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive drug monotherapies
Study: 18400141
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg kg(‐1) in 10 mL normal saline)
Study: 18400141
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 microg kg(‐1) in 10 mL normal saline)
Study: 11985532
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose immunosuppression (after tapering)
Study: 9307633
Drug: 0.3% carbomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% carbomer gel
Study: 9307633
Drug: placebo (mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (mannitol solution with benzalkonium chloride 0.008%)
Study: 9307633
Drug: carbomer gel
DrugBank: Carbomer (DB15649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbomer gel and placebo
Study: 27309886
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (240 mg in 125 mL saline solution)
Study: 27309886
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (125 mL saline solution)
Study: 18068284
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (Methylphenidate + Psychosocial treatments)
Study: 18068284
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Methylphenidate, Psychosocial treatments, Combined treatments)
Study: 15528979
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of GW572016
Study: 15528979
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of GW572016 (25 mg, 100 mg, 175 mg)
Study: 12629229
Drug: alpha‐[11C] methyl‐L‐tryptophan
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐[11C] methyl‐L‐tryptophan (alpha‐MTrp) PET
Study: 8561642
Drug: Heparin-coated oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated oxygenator
Study: 24060179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EGFR/p16
Study: 21263371
Drug: Cefazolin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (two doses during removal of the catheter)
Study: 7404301
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial agent (control group)
Study: 19208352
Drug: Low-carbohydrate (LC)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate (LC) diet (<50 g/day)
Study: 19208352
Drug: Low-fat, high-carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-carbohydrate (HC) diet (>180 g/day)
Study: 18667140
Drug: Various nonpharmacologic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various nonpharmacologic interventions and therapies tried by patients, including assessment of success rates and patient function.
Study: 15363824
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (20 nonpharmacologic, 36 beta‐blockers, 33 angiotensin receptor blocker)
Study: 15363824
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment after 12 months
Study: 11181662
Drug: IV carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV carboplatin (area under curve 9) every 28 days for two courses, then IV paclitaxel 135 mg/m(2) over 24 hours followed by intraperitoneal (IP) cisplatin 100 mg/m(2) every 3 weeks for six courses
Study: 11181662
Drug: IV cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV cisplatin 75 mg/m(2) every 3 weeks for six courses plus IV paclitaxel 135 mg/m(2) over 24 hours
Study: 9692280
Drug: Organization and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organization and administration issues studies
Study: 3931107
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lorazepam
Study: 11960
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg papaveretum/400 mug hyoscine
Study: 28185260
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg sugammadex (Group S)
Study: 28185260
Drug: 0.35 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35 mg/kg neostigmine and 0.02 mg/kg atropine (Group N)
Study: 23380907
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture as adjunct to reversible occlusal splint therapy
Study: 23380907
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser associated with occlusal splint therapy
Study: 4037555
Drug: Weekly pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly pulse methotrexate
Study: 28887640
Drug: G10 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: G10 group received two IV doses of 10 mg/kg of TXA
Study: 28887640
Drug: G20 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: G20 group received two doses of 20 mg/kg of TXA
Study: 25263395
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (12% ethanol, 1758 mg/L total polyphenols) for 4 weeks
Study: 23051744
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) 7.5 g divided into three daily doses
Study: 15715969
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 100 mg, single dose
Study: 15715969
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200 mg, single dose
Study: 15715969
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 400 mg, single dose
Study: 14609883
Drug: Olanzapine, 5
Normalized name: Olanzapine, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine, 5 to 20 mg/d
Study: 14609883
Drug: Olanzapine-fluoxetine combination,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d
Study: 14609883
Drug: Olanzapine-fluoxetine vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine-fluoxetine vs Olanzapine
Study: 14609883
Drug: Treatment-emergent mania
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent mania
Study: 14609883
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events for olanzapine-fluoxetine
Study: 18614998
Drug: HAART (highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART (highly active antiretroviral therapy)
Study: 1375598
Drug: Synthetic porcine
Normalized name: Secretin synthetic porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic porcine galanin (0.5 mg in 100 mL saline)
Study: 1375598
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (100 mL saline)
Study: 3893700
Drug: 1% Clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Clotrimazole cream
Study: 31142044
Drug: 10 mg-Zn/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg-Zn/day
Study: 31142044
Drug: 5 mg-Zn/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg-Zn/day
Study: 28991918
Drug: No stool
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stool testing and placebo treatment
Study: 25620670
Drug: Step-up treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up treatment after endoscopic recurrence
Study: 23521325
Drug: Avanafil 100/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil 100/200 mg
Study: 11773989
Drug: Eprosartan 300
Normalized name: eprosartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 300 mg twice daily
Study: 9924262
Drug: Lower-carbohydrate test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-carbohydrate test meal (0.5 g fat/kg body weight + 17 g carbohydrate as lactose)
Study: 9924262
Drug: Higher-carbohydrate test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-carbohydrate test meal (0.5 g fat/kg body weight + 136 g carbohydrate, 60 g sucrose)
Study: 29652551
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg of fish-derived n-3 eicosapentaenoic and docosahexaenoic acids
Study: 28912192
Drug: Pharmacological cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological cervical ripening with Propess system (10 mg of dinoprostone, Ferring SAS, France) before oxytocin administration
Study: 21443600
Drug: Alitretinoin 40
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 40 mg after fasting (treatment A)
Study: 21443600
Drug: Alitretinoin 40
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 40 mg after a standard breakfast (treatment B)
Study: 19563951
Drug: Azithromycin 600
Normalized name: azithromycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 600 mg once daily for 3 days and then 600 mg once weekly for 15 weeks
Study: 19563951
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of statins and acetylsalicylic acid (ASA)
Study: 17147908
Drug: Antiviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral agents (specifically aciclovir)
Study: 17147908
Drug: Antiviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral agents for post-exposure prophylaxis
Study: 9062617
Drug: etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg kg‐1 for induction of anaesthesia
Study: 8400493
Drug: Allopurinol 50
Normalized name: allopurinol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 50 mg 4 times daily
Study: 8400493
Drug: DMSO 500
Normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMSO 500 mg 4 times daily